Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.60 |
| ▸ | F2 | P00734 | 1/20 | 0.59 |
| ▸ | F12 | P00748 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7075310 | 0.86 | ALDH1A1 (0.50) | GAAF2F12ALDH1A1MAPT | |
| SCHEMBL7244914 | 0.85 | ALDH1A1 (0.56) | GAAF2F12ALDH1A1MAPT | |
| SCHEMBL821809 | 0.84 | F2 (0.52) | GAAF2F12ALDH1A1MAPT | |
| SCHEMBL24756637 | 0.83 | F2 (0.48) | GAAF2F12ALDH1A1MAPT | |
| SCHEMBL6820113 | 0.83 | MEN1 (0.50) | GAAF2F12ALDH1A1MAPT | |
| SCHEMBL15890202 | 0.82 | NPC1 (0.54) | GAAF2F12ALDH1A1MAPT | |
| SCHEMBL15899961 | 0.82 | GAA (0.47) | GAAF2F12ALDH1A1CCNE1 | |
| SCHEMBL1011540 | 0.82 | RAB9A (0.59) | GAAF2F12ALDH1A1MAPT | |
| SCHEMBL31286005 | 0.82 | RAB9A (0.59) | GAAF2F12ALDH1A1MAPT | |
| SCHEMBL31125168 | 0.80 | F2 (0.46) | GAAF2F12ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651872-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | Septerna, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-2024155601-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | SEPTERNA, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| US-10913734-B2 | Substituted aminothiazoles | BARUCH S. BLUMBERG INSTITUTE | 2021-02-09 | — | — | US | disclosed |
| US-10913734-B2 | Substituted aminothiazoles | BARUCH S. BLUMBERG INSTITUTE | 2021-02-09 | — | — | US | disclosed |
| EP-3221317-B1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-07-22 | — | — | EP | disclosed |
| EP-3221317-B1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-07-22 | — | — | EP | disclosed |
| CN-107207509-B | Substituted bridged ring urea analogs as sirtuin modulators | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2020-04-21 | — | — | CN | disclosed |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190241552-A1 | SUBSTITUTED AMINOTHIAZOLES | BARUCH S. BLUMBERG INSTITUTE | 2019-08-08 | — | — | US | disclosed |
| EP-1430040-A1 | BENZOTHIAZEPINE DERIVATIVES | Astrazeneca AB (SE) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003020710-A1 | BENZOTHIAZEPINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-03-13 | — | — | WO | disclosed |
| WO-2002062768-A1 | HERBICIDAL SULFONYLUREAS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2002-08-15 | — | — | WO | disclosed |
| WO-1999032454-A9 | NITROGEN CONTAINING HETEROAROMATICS WITH ORTHO-SUBSTITUTED P1'S AS FACTOR XA INHIBITORS | DU PONT PHARM CO (US) | 2001-05-31 | — | — | WO | disclosed |
| US-5220062-A | PROCESS FOR THE PREPARATION OF BENEZENESULFONAMIDES | CIBA-GEIGY CORPORATION (US) | 1993-06-15 | — | — | US | disclosed |
| EP-0168005-B1 | SEMICARBAZIDE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-04-18 | — | — | EP | disclosed |
| US-4694004-A | ANALGESICS; ANTIINFLAMMATORY AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-15 | — | — | US | disclosed |
| EP-0099770-B1 | OXAZINOBENZOTHIAZINE-6,6-DIOXIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENT | PROVESAN S.A. (CH) | 1986-08-27 | — | — | EP | disclosed |
| EP-0168005-A2 | Semicarbazide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-01-15 | — | — | EP | disclosed |
| US-4563452-A | ANTIINFLAMMATORY, ANALGESIC | PROVESAN S.A. (CH) | 1986-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913734-B2 | Substituted aminothiazoles | ABAT, AADAT, BCAT1 | GAA 3355/4885F2 3232/4885F12 4502/4885 |
| US-20190241552-A1 | SUBSTITUTED AMINOTHIAZOLES | ABAT, AADAT, BCAT1 | GAA 3355/4885F2 3232/4885F12 4502/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | GAA 1368/4885F2 693/4885F12 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.